title: Ezetimibe for lowering blood cholesterol.
abstract: Ezetimibe is the first drug in a new class called cholesterol absorption inhibitors. There is no evidence that ezetimibe will reduce rates of death or hospitalization. When it is taken alone or when it is added to existing statin therapy, ezetimibe can reduce serum cholesterol in patients who have an increased risk of future coronary artery disease. The safety and tolerability of ezetimibe alone or combined with a statin has not been established in trials beyond 12 weeks.
authors.forename: Don R
authors.initials: DR
authors.lastname: Husereau
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001384:Azetidines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002170:Canada; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines